Feasibility of T-Cell-Based Adoptive Immunotherapy in the First 12 Patients with Advanced Urothelial Urinary Bladder Cancer. Preliminary Data on a New Immunologic Treatment Based on the Sentinel Node Concept

European Urology

Volumn 58, Issue 1, 2010, Pages 105-111

  Sherif, Amir ^a   Hasan, Mudhar N ^a   Marits, Per ^b   Karlsson, Mona ^c   Winqvist, Ola ^b   Thörn, Magnus ^d,e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SentoClone AB   (Sweden)

^d STOCKHOLM SÖDER HOSPITAL   (Sweden)

^e UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Adoptive immunotherapy; Metinel node; Sentinel node; Urinary bladder cancer

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER STAGING; CELL EXPANSION; CLINICAL ARTICLE; CYSTECTOMY; FEMALE; HELPER CELL; HUMAN; INFUSION; LYMPH NODE; LYMPHADENECTOMY; LYMPHOCYTE CULTURE; MALE; METASTASIS; METINEL LYMPH NODE; OVERALL SURVIVAL; PATIENT SELECTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENTINEL LYMPH NODE;

AGED; ANTIGEN-PRESENTING CELLS; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LYMPH NODES; LYMPHOCYTE ACTIVATION; MALE; NEOPLASM STAGING; PILOT PROJECTS; PROSPECTIVE STUDIES; T-LYMPHOCYTES, HELPER-INDUCER; URINARY BLADDER NEOPLASMS;

EID: 77952876315     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.09.026     Document Type: Article

References (24)

1. Ploeg M., Aben K.K., and Kiemeney L.A. The present and future burden of urinary bladder cancer in the world. World J Urol 27 (2009) 289-293
2. Holmäng S., Hedelin H., Anderström C., and Johansson S.L. Long-term follow-up of all patients with muscle invasive (stages T2, T3 and T4) bladder carcinoma in a geographical region. J Urol 158 (1997) 389-392
3. Prout Jr. G.R., Griffin P.P., and Shipley W.U. Bladder carcinoma as a systemic disease. Cancer 43 (1979) 2532-2539
4. Stein J.P., and Skinner D.G. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol 24 (2006) 296-304
5. Cabanas R.M. An approach for the treatment of penile carcinoma. Cancer 39 (1977) 456-466
6. Mosca P.J., Tyler D.S., and Seigler H.F. Surgical management of cutaneous melanoma: current practice and impact on prognosis. Adv Surg 38 (2004) 85-119
7. Veronesi U., Paganelli G., Galimberti V., et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet 349 (1997) 1864-1867
8. Sherif A., De La Torre M., Malmstrom P.U., and Thörn M. Lymphatic mapping and detection of sentinel nodes in patients with bladder cancer. J Urol 166 (2001) 812-815
9. Liedberg F., Chebil G., Davidsson T., Gudjonsson S., and Månsson W. Intraoperative sentinel node detection improves nodal staging in invasive bladder cancer. J Urol 175 (2006) 84-88
10. Sherif A., Garske U., De La Torre M., and Thörn M. Hybrid SPECT-CT: an additional technique for sentinel node detection of patients with invasive bladder cancer. Eur Urol 50 (2006) 83-91
11. Burnet F.M. The concept of immunological surveillance. Prog Exp Tumor Res 13 (1970) 1-27
12. Ratliff T.L., Ritchey J.K., Yuan J.J., Andriole G.L., and Catalona W.J. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 150 (1993) 1018-1023
13. Mangsbo S.M., Ninalga C., Essand M., Loskog A., and Tötterman T.H. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity. J Immunother 31 (2008) 34-42
14. Marits P., Karlsson M., Sherif A., Garske U., Thörn M., and Winqvist O. Detection of immune responses against urinary bladder cancer in sentinel lymph nodes. Eur Urol 49 (2006) 59-70
15. Dahl K., Karlsson M., Marits P., Hoffstedt A., Winqvist O., and Thörn M. Metinel node-the first lymph node draining a metastasis-contains tumor-reactive lymphocytes. Ann Surg Oncol 15 (2008) 1454-1463
16. Antony P.A., Piccirillo C.A., Akpinarli A., et al. CD8+ T-cell immunity against a tumor/self-antigen is augmented by CD4+ T-helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174 (2005) 2591-2601
17. Janssen E.M., Droin N.M., Lemmens E.E., et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434 (2005) 88-93
18. Surman D.R., Dudley M.E., Overwijk W.W., and Restifo N.P. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol 164 (2000) 562-565
19. Marits P., Karlsson M., Dahl K., et al. Sentinel node lymphocytes: tumor reactive lymphocytes identified intraoperatively for the use in immunotherapy of colon cancer. Br J Cancer 94 (2006) 1478-1484
20. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol 48 (2005) 202-206
21. Sherif A., Holmberg L., Rintala E., et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 45 (2004) 297-303
22. Wallmeroth A., Wagner U., Moch H., Gasser T.C., Sauter G., and Mihatsch M.J. Patterns of metastasis in muscle-invasive bladder cancer (pT2-4): an autopsy study on 367 patients. Urol Int 62 (1999) 69-75
23. Swinnen G., Maes A., Pottel H., et al. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol 57 (2010) 641-647
24. Brandacher G., Perathoner A., Ladurner R., et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 12 (2006) 1144-1151